Sugi Predict

Sugi Predict / Compounds / SCHEMBL24558288

SCHEMBL24558288

SCHEMBL24558288

Cc1cc2c(cc1Br)OC[C@H]1CN(C(=O)OC(C)(C)C)CCN1C2=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.40
▸ USP30 Q70CQ3 4/20 0.39
▸ TP53 P04637 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.37
▸ FPR2 P25090 3/20 0.36
▸ SMARCA2 P51531 1/20 0.35
▸ SMARCA4 P51532 1/20 0.35
▸ PBRM1 Q86U86 1/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.34
▸ KRAS P01116 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ SETD7 Q8WTS6 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ ABCB1 P08183 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24558178 0.90 USP30 (0.39) LMNAUSP30TP53GPR119FPR2
SCHEMBL26041621 0.89 USP30 (0.39) USP30TP53FPR2SMARCA2SMARCA4
SCHEMBL23512857 0.89 USP30 (0.39) USP30TP53FPR2SMARCA2SMARCA4
SCHEMBL23512534 0.89 USP30 (0.39) USP30TP53FPR2SMARCA2SMARCA4
SCHEMBL29693184 0.89 USP30 (0.39) USP30TP53FPR2SMARCA2SMARCA4
SCHEMBL4410957 0.86 FPR2 (0.42) USP30TP53GPR119FPR2SMARCA2
SCHEMBL28664244 0.85 KRAS (0.37) KRAS
SCHEMBL4409882 0.85 FPR2 (0.43) USP30TP53FPR2SMARCA2SMARCA4
SCHEMBL4411908 0.85 TP53 (0.46) LMNAUSP30TP53GPR119SMARCA2
SCHEMBL4408792 0.84 TP53 (0.46) LMNAUSP30TP53GPR119SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents ASTRAZENECA AB (SE) 2025-09-09 — — US disclosed
CN-113508118-B Fused tricyclic compounds useful as anticancer agents 阿斯利康(瑞典)有限公司 2024-07-19 — — CN disclosed
EP-3935060-B1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2023-11-15 — — EP disclosed
EP-3935060-B1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2023-11-15 — — EP disclosed
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA UK LIMITED (GB) 2022-06-30 — — US disclosed
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS ASTRAZENECA UK LIMITED (GB) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents MCL1, TP53, CCNA2 LMNA 853/4885USP30 4265/4885TP53 2/4885
US-20220204527-A1 FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS MCL1, TP53, CCNA2 LMNA 853/4885USP30 4265/4885TP53 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.